NASDAQ:VERV Verve Therapeutics (VERV) Stock Forecast, Price & News $17.95 +1.21 (+7.23%) (As of 06/6/2023 ET) Add Compare Share Share Today's Range$16.68▼$18.1950-Day Range$13.34▼$18.4152-Week Range$10.70▼$43.00Volume633,229 shsAverage Volume687,537 shsMarket Capitalization$1.11 billionP/E RatioN/ADividend YieldN/APrice Target$38.63 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Verve Therapeutics MarketRank™ ForecastAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside114.0% Upside$38.63 Price TargetShort InterestBearish31.20% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.91Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($3.50) to ($3.84) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.93 out of 5 starsMedical Sector662nd out of 984 stocksPharmaceutical Preparations Industry316th out of 472 stocks 3.3 Analyst's Opinion Consensus RatingVerve Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 5 buy ratings, 2 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $38.63, Verve Therapeutics has a forecasted upside of 114.0% from its current price of $18.05.Amount of Analyst CoverageVerve Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted31.20% of the float of Verve Therapeutics has been sold short.Short Interest Ratio / Days to CoverVerve Therapeutics has a short interest ratio ("days to cover") of 16.7, which indicates bearish sentiment.Change versus previous monthShort interest in Verve Therapeutics has recently decreased by 3.96%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldVerve Therapeutics does not currently pay a dividend.Dividend GrowthVerve Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for VERV. Previous Next 3.3 News and Social Media Coverage News SentimentVerve Therapeutics has a news sentiment score of 0.91. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Verve Therapeutics this week, compared to 3 articles on an average week.Search Interest9 people have searched for VERV on MarketBeat in the last 30 days. This is an increase of 350% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added Verve Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Verve Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders21.40% of the stock of Verve Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions98.52% of the stock of Verve Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Verve Therapeutics are expected to decrease in the coming year, from ($3.50) to ($3.84) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Verve Therapeutics is -5.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Verve Therapeutics is -5.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVerve Therapeutics has a P/B Ratio of 2.02. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Verve Therapeutics (NASDAQ:VERV) StockVerve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.Read More Receive VERV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Verve Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address VERV Stock News HeadlinesJune 5, 2023 | fortune.comExclusive: GV promotes 4 new general partners as the firm gears up for ‘the next 15 years’June 1, 2023 | fool.comVerve Therapeutics (NASDAQ: VERV)June 6, 2023 | Behind the Markets (Ad)BREAKING: Tiny biotech successfully treats blindnessThere's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.June 1, 2023 | finance.yahoo.comVerve Therapeutics to Participate in the 2023 Jefferies Healthcare ConferenceMay 23, 2023 | finance.yahoo.comVerve Therapeutics to Participate in the Stifel 2023 Tailoring Genes: Virtual Genetic Medicines DayMay 21, 2023 | americanbankingnews.comCantor Fitzgerald Analysts Lower Earnings Estimates for Verve Therapeutics, Inc. (NASDAQ:VERV)May 20, 2023 | americanbankingnews.comQ2 2023 EPS Estimates for Verve Therapeutics, Inc. (NASDAQ:VERV) Lowered by William BlairMay 18, 2023 | bizjournals.comBoston Business Journal unveils 2023 CFOs of the YearJune 6, 2023 | Behind the Markets (Ad)How A.I. Could Make Most 21st Century Diseases EXTINCTOn December 22, 2022, AI discovered a new treatment for multiple myeloma... in just 4 months... On March 19, 2023, AI discovered a new drug for liver cancer... in only 30 days... There's one small-cap at the center of it all. Bill Gates owns 7 million shares... Billionaire hedge-fund manager Steve Cohen owns 1.4 million shares...May 18, 2023 | seekingalpha.comVerve Therapeutics (VERV) Presents at TIDES 2023 - SlideshowMay 18, 2023 | americanbankingnews.comVerve Therapeutics (NASDAQ:VERV) Posts Earnings Results, Misses Expectations By $0.07 EPSMay 18, 2023 | americanbankingnews.comVerve Therapeutics (NASDAQ:VERV) Trading Down 7.8% After Earnings MissMay 17, 2023 | americanbankingnews.comBrokerages Set Verve Therapeutics, Inc. (NASDAQ:VERV) PT at $38.63May 16, 2023 | msn.comRBC Capital Reiterates Verve Therapeutics (VERV) Outperform RecommendationMay 15, 2023 | markets.businessinsider.comLifeSci Capital Remains a Buy on Verve Therapeutics (VERV)May 15, 2023 | finance.yahoo.comVerve Therapeutics (VERV) Reports Q1 Loss, Tops Revenue EstimatesMay 15, 2023 | finance.yahoo.comVerve Therapeutics Announces Pipeline Progress and Expansion and Reports First Quarter 2023 Financial ResultsMay 11, 2023 | finance.yahoo.comWe're Not Very Worried About Verve Therapeutics' (NASDAQ:VERV) Cash Burn RateMay 9, 2023 | finance.yahoo.comVerve Therapeutics to Participate in the RBC Capital Markets 2023 Global Healthcare ConferenceApril 26, 2023 | americanbankingnews.comVerve Therapeutics (NASDAQ:VERV) Trading Down 4.4%April 20, 2023 | markets.businessinsider.comLifeSci Capital Keeps Their Buy Rating on Verve Therapeutics (VERV)April 20, 2023 | finance.yahoo.comTop 10 CRISPR Stocks To BuyApril 20, 2023 | americanbankingnews.comVerve Therapeutics, Inc. (NASDAQ:VERV) Receives $38.63 Average Target Price from AnalystsApril 18, 2023 | seekingalpha.comVERV Verve Therapeutics, Inc.April 15, 2023 | americanbankingnews.comVerve Therapeutics (NASDAQ:VERV) Trading Up 7.6%April 14, 2023 | seekingalpha.comVerve: Spiffy Biotech That Cathie Wood Bought, Initiating With A Hold RatingApril 14, 2023 | msn.comCanaccord Genuity Initiates Coverage of Verve Therapeutics (VERV) with Buy RecommendationSee More Headlines VERV Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VERV Company Calendar Last Earnings5/15/2023Today6/06/2023Next Earnings (Estimated)8/08/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:VERV CUSIPN/A CIK1840574 Webvervetx.com Phone617-603-0070FaxN/AEmployees113Year FoundedN/APrice Target and Rating Average Stock Price Forecast$38.63 High Stock Price Forecast$62.00 Low Stock Price Forecast$13.00 Forecasted Upside/Downside+114.0%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($3.14) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-157,390,000.00 Net MarginsN/A Pretax Margin-5,355.54% Return on Equity-37.63% Return on Assets-31.01% Debt Debt-to-Equity RatioN/A Current Ratio15.43 Quick Ratio15.43 Sales & Book Value Annual Sales$1.94 million Price / Sales576.11 Cash FlowN/A Price / Cash FlowN/A Book Value$8.94 per share Price / Book2.02Miscellaneous Outstanding Shares61,920,000Free Float48,668,000Market Cap$1.12 billion OptionableNot Optionable Beta1.46 Key ExecutivesDr. Sekar Kathiresan M.D. (Age 50)Co-Founder, CEO & Director Comp: $986.58kDr. Anthony Philippakis M.D.Ph.D., Co-Founder & Scientific Advisory Board MemberMs. Allison Dorval (Age 46)CFO & Principal Accounting Officer Comp: $260.93kDr. Andrew Bellinger M.D. (Age 44)Ph.D., Chief Scientific Officer & Chief Medical Officer Comp: $727.2kMr. Andrew D. Ashe J.D. (Age 55)Pres & COO Dr. Kiran Musunuru M.D.M.P.H., Ph.D., Co-Founder & Sr. Scientific AdvisorDr. J. Keith Joung M.D.Ph.D., Co-FounderDr. Barry S. Ticho FACC (Age 61)M.D., Ph.D., Co-Founder Mr. Issi Rozen M.B.A.Co-Founder & Strategic AdvisorMs. Margaret Beaudoin (Age 53)VP of Fin. More ExecutivesKey CompetitorsCassava SciencesNASDAQ:SAVARhythm PharmaceuticalsNASDAQ:RYTMKiniksa PharmaceuticalsNASDAQ:KNSAAvid BioservicesNASDAQ:CDMOPOINT Biopharma GlobalNASDAQ:PNTView All CompetitorsInsiders & InstitutionsAmeriprise Financial Inc.Bought 15,766 shares on 5/22/2023Ownership: 0.092%JPMorgan Chase & Co.Bought 119,902 shares on 5/18/2023Ownership: 3.082%New York State Common Retirement FundSold 5,687 shares on 5/18/2023Ownership: 0.040%Geode Capital Management LLCBought 38,038 shares on 5/16/2023Ownership: 1.431%Hudson Bay Capital Management LPBought 29,000 shares on 5/16/2023Ownership: 0.047%View All Insider TransactionsView All Institutional Transactions VERV Stock - Frequently Asked Questions Should I buy or sell Verve Therapeutics stock right now? 8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Verve Therapeutics in the last year. There are currently 1 sell rating, 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" VERV shares. View VERV analyst ratings or view top-rated stocks. What is Verve Therapeutics' stock price forecast for 2023? 8 Wall Street research analysts have issued 1 year price objectives for Verve Therapeutics' stock. Their VERV share price forecasts range from $13.00 to $62.00. On average, they expect the company's stock price to reach $38.63 in the next twelve months. This suggests a possible upside of 114.0% from the stock's current price. View analysts price targets for VERV or view top-rated stocks among Wall Street analysts. How have VERV shares performed in 2023? Verve Therapeutics' stock was trading at $19.35 on January 1st, 2023. Since then, VERV stock has decreased by 6.7% and is now trading at $18.05. View the best growth stocks for 2023 here. When is Verve Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023. View our VERV earnings forecast. How were Verve Therapeutics' earnings last quarter? Verve Therapeutics, Inc. (NASDAQ:VERV) released its quarterly earnings results on Monday, May, 15th. The company reported ($0.84) earnings per share for the quarter, missing the consensus estimate of ($0.77) by $0.07. The firm earned $1.40 million during the quarter, compared to the consensus estimate of $1 million. What ETFs hold Verve Therapeutics' stock? ETFs with the largest weight of Verve Therapeutics (NASDAQ:VERV) stock in their portfolio include Kelly CRISPR & Gene Editing Technology ETF (XDNA), ARK Genomic Revolution ETF (ARKG), Global X Genomics & Biotechnology ETF (GNOM), WisdomTree BioRevolution Fund (WDNA), Virtus LifeSci Biotech Clinical Trials ETF (BBC), SPDR S&P Biotech ETF (XBI), Direxion Daily S&P Biotech Bull 3x Shares (LABU) and ARK Innovation ETF (ARKK). When did Verve Therapeutics IPO? (VERV) raised $201 million in an IPO on Thursday, June 17th 2021. The company issued 11,800,000 shares at $16.00-$18.00 per share. J.P. Morgan, Jefferies, Guggenheim Securities and William Blair served as the underwriters for the IPO. What is Verve Therapeutics' stock symbol? Verve Therapeutics trades on the NASDAQ under the ticker symbol "VERV." Who are Verve Therapeutics' major shareholders? Verve Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include FMR LLC (11.03%), ARK Investment Management LLC (7.25%), BlackRock Inc. (5.73%), State Street Corp (5.41%), Federated Hermes Inc. (3.88%) and JPMorgan Chase & Co. (3.08%). Insiders that own company stock include 2017 Gp LLC Gv, Allison Dorval, Andrew Bellinger, Andrew D Ashe, Burt A Adelman, Cormorant Asset Management, Lp, Fmr Llc, Krishna Yeshwant, Logos Global Management Lp and Sekar Kathiresan. View institutional ownership trends. How do I buy shares of Verve Therapeutics? Shares of VERV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Verve Therapeutics' stock price today? One share of VERV stock can currently be purchased for approximately $18.05. How much money does Verve Therapeutics make? Verve Therapeutics (NASDAQ:VERV) has a market capitalization of $1.12 billion and generates $1.94 million in revenue each year. The company earns $-157,390,000.00 in net income (profit) each year or ($3.14) on an earnings per share basis. How many employees does Verve Therapeutics have? The company employs 113 workers across the globe. How can I contact Verve Therapeutics? The official website for the company is vervetx.com. The company can be reached via phone at 617-603-0070 or via email at ir@vervetx.com. This page (NASDAQ:VERV) was last updated on 6/6/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Verve Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.